CASTLE ROCK, Colo., Dec. 20 /PRNewswire-FirstCall/ -- AspenBio Pharma,
Inc. (Nasdaq: APPY) an emerging bio-pharmaceutical company dedicated to the
development of novel drugs and diagnostics for animals and humans, today
announced that it has entered into securities purchase agreements in
connection with a private placement with a group of existing and new
investors. Under the terms of the agreement, AspenBio will receive
approximately $18 million in gross proceeds from the sale of approximately
2.5 million shares of its common stock.
Subject to the satisfaction of customary closing conditions, the
transaction is expected to close on or about December 24, 2007. Net
proceeds from the transaction will be used to fund research and
development, product development, FDA approval related activities, working
capital and general corporate purposes.
The shares of AspenBio's common stock issued in connection with the
private placement have not been registered under the Securities Act of
1933, as amended (the "Securities Act"). Accordingly, these securities may
not be offered or sold in the United States except pursuant to an effective
registration statement or an applicable exemption from the registration
requirements of the Securities Act. AspenBio has agreed to file within 30
days after the closing one or more registration statements covering the
resale of the common stock. This press release shall not constitute an
offer to sell or the solicitation of an offer to buy AspenBio's common
About AspenBio Pharma, Inc.
AspenBio Pharma is an emerging bio-pharmaceutical company dedicated to
the discovery; development, manufacture, and marketing of novel proprietary
products, including those that enhance the reproductive efficiency of
animals and that have large worldwide market potential. The company was
originally formed to produce purified proteins for diagnostic applications
and has become a leading supplier of human hormones to many of the nation's
largest medical diagnostic companies and research institutions. The company
has successfully leveraged this foundational science and technology
expertise to rapidly develop an enviable late-stage pipeline of several
novel reproduction hormone analogs for wide-ranging therapeutic use
initially in bovine and equine species. AspenBio Pharma continues to
advance the development and testing of its two first-generation blood-based
human diagnostic tests designed to rapidly help diagnose or rule out
appendicitis in patients complaining of abdominal pain. For more
information, please visit: http://www.aspenbiopharma.com.
Forward Looking Statements
This news release includes "forward looking statements" of AspenBio
Pharma, Inc. ("APPY") as defined by the Securities and Exchange Commission
(the "SEC"). All statements, other than statements of historical fact,
included in the press release that address activities, events or
developments that APPY believes or anticipates will or may occur in the
future are forward-looking statements. These statements are based on
certain assumptions made based on experience, expected future developments
and other factors APPY believes are appropriate in the circumstances. Such
statements are subject to a number of assumptions, risks and uncertainties,
many of which are beyond the control of APPY. Investors are cautioned that
any such statements are not guarantees of future performance. Actual
results or developments may differ materially from those projected in the
forward-looking statements as a result of many factors, including
statements regarding the private placement, the expected closing of the
private placement and the ability to successfully complete the development
of, obtain FDA approval for and generate revenues from the appendicitis
test and other new products, execute agreements required to successfully
advance the company's objectives, retain the scientific management team to
advance the products, overcome adverse changes in market conditions and the
regulatory environment, fluctuations in sales volumes, obtain and enforce
intellectual property rights, and realization of intangible assets.
Furthermore, APPY does not intend (and is not obligated) to update publicly
any forward-looking statements. The contents of this news release should be
considered in conjunction with the warnings and cautionary statements
contained in APPY's recent filings with the SEC.
For more information contact:
AspenBio Pharma, Inc.
Gregory Pusey, Chairman
Liolios Group, Inc.
Scott Liolios or Ron Both
SOURCE AspenBio Pharma, Inc.